Researchers raise concerns about faster ageing, possible early-onset dementia, for children and young adult cancer survivors
Adolescent and young adult cancer survivors age faster than their peers who did not have…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Survival outcomes in young adults with metastatic colorectal cancer vary by socioeconomic context
A large cohort study published in JAMA Network Open has documented significant disparities in survival…
$280 million towards innovative health and medical research
The Albanese Government is investing almost $280 million in health and medical research projects to…
Personalised genetic risk counselling improves understanding but not surgical decisions in breast cancer
A randomised clinical trial published in JAMA Network Open has found that personalised genetic risk…
Defining and addressing loneliness in older adults with cancer
Research published in The Lancet Healthy Longevity highlights loneliness as an important but under-recognised issue…
Gut bacteria from tree frogs: unexplored biodiversity could represent a treasure trove for novel medical technology
A research team of Prof. Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST)…
Anti-diabetic drugs and their surprising impact on cancer progression
This research delves into the association between anti-diabetic medications and cancer, exploring mechanisms beyond just…
S3E11 The Oncology Journal Club: End of Year Special
Welcome to Episode 11 of The Oncology Journal Club! Our Host Craig Underhill is joined by Dr Kate Clarke and Professor Christopher Jackson. Join the team for some fun, festive antics!
SABCS 2025: Adding tucatinib to first-line maintenance therapy delayed disease progression in HER2-positive metastatic breast cancer in HER2CLIMB-05 trial
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease…
SABCS 2025: A multimodal AI model may improve recurrence risk stratification in early breast cancer
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved…